You are here

Padcev

FDA starts review of Padcev/Keytruda for bladder cancer

FDA starts review of Padcev/Keytruda for bladder cancer

Pharmaphorum

priority review

Flag link:

Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO

Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO

BioSpace

Bristol Myers Squibb

PD-1 inhibitors

Flag link:

ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow

ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow

Fierce Pharma

Bristol Myers Squibb

Flag link:

ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

ESMO: Seagen, Astellas and Merck knock it out of the park with Padcev-Keytruda combo in bladder cancer

Fierce Pharma

Flag link:

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo

BioSpace

urothelial cancer

clinical trials

Flag link:

FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer

FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer

BioSpace

metastatic urothelial carcinoma

Flag link:

ASCO-GU – Bicycle tries to put distance between itself and Seagen

ASCO-GU – Bicycle tries to put distance between itself and Seagen

EP Vantage

Bicycle Therapeutics

urothelial cancer

Flag link:

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

Fierce Biotech

Corbus Pharmaceuticals

Flag link:

ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda

ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda

Fierce Pharma

urothelial cancer

Flag link:

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe

Yahoo/Zacks.com

Flag link:

Seagen, Astellas claim positive results in study key to cancer drug's success

Seagen, Astellas claim positive results in study key to cancer drug's success

BioPharma Dive

clinical trials

Flag link:

Trial win sets up new use for Astellas, Seagen’s Padcev in bladder cancer

Trial win sets up new use for Astellas, Seagen’s Padcev in bladder cancer

Pharmaforum

clinical trials

Flag link:

FDA Approvals Roundup: Kerendia, Padcev, Darzalex Faspro

FDA Approvals Roundup: Kerendia, Padcev, Darzalex Faspro

RAPS.org

Teva Pharmaceutical

ArmonAir RespiClick

Darzalex Faspro

Flag link:

Seagen, Astellas' Padcev snares full approval and expands into second-line treatment on path to blockbuster land

Seagen, Astellas' Padcev snares full approval and expands into second-line treatment on path to blockbuster land

Fierce Pharma

Flag link:

#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data

#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data

Endpoints

urothelial cancer

Flag link:

Seagen gets August PDUFA for Padcev expansions

Seagen gets August PDUFA for Padcev expansions

Endpoints

Flag link:

Asco-GU – confirmatory Padcev trial throws a curveball

Asco-GU – confirmatory Padcev trial throws a curveball

EP Vantage

Flag link:

Seattle Genetics stays step ahead of rivals with bladder cancer data

Seattle Genetics stays step ahead of rivals with bladder cancer data

BioPharma Dive

Seattle Genetics

clinical trials

Flag link:

Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water

Seattle Genetics' bladder cancer med Padcev blows early expectations out of the water

Fierce Pharma

Seattle Genetics

Flag link:

Seattle Genetics Issue Update on Padcev Label Expansion Study

Seattle Genetics Issue Update on Padcev Label Expansion Study

Yahoo/Zacks.com

Seattle Genetics

urothelial cancer

Flag link:

Pages